131 related articles for article (PubMed ID: 19503932)
1. Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
Carbain B; Martin SR; Collins PJ; Hitchcock PB; Streicher H
Org Biomol Chem; 2009 Jun; 7(12):2570-5. PubMed ID: 19503932
[TBL] [Abstract][Full Text] [Related]
2. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
3. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Liu H; Yao X; Wang C; Han J
Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: A comparative structural analysis by the ScrewFit algorithm.
Calligari PA; Kneller GR; Giansanti A; Ascenzi P; Porrello A; Bocedi A
Biophys Chem; 2009 Apr; 141(1):117-23. PubMed ID: 19195766
[TBL] [Abstract][Full Text] [Related]
5. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Abed Y; Nehmé B; Baz M; Boivin G
Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
[TBL] [Abstract][Full Text] [Related]
6. Biotin-, fluorescein- and 'clickable' conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase.
Stanley M; Martin SR; Birge M; Carbain B; Streicher H
Org Biomol Chem; 2011 Aug; 9(16):5625-9. PubMed ID: 21720632
[TBL] [Abstract][Full Text] [Related]
7. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
Park JW; Jo WH
Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity.
Shie JJ; Fang JM; Wang SY; Tsai KC; Cheng YS; Yang AS; Hsiao SC; Su CY; Wong CH
J Am Chem Soc; 2007 Oct; 129(39):11892-3. PubMed ID: 17850083
[No Abstract] [Full Text] [Related]
9. Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza.
Albiñana CB; Machara A; Řezáčová P; Pachl P; Konvalinka J; Kožíšek M
Eur J Med Chem; 2016 Oct; 121():100-109. PubMed ID: 27236066
[TBL] [Abstract][Full Text] [Related]
10. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
[No Abstract] [Full Text] [Related]
11. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Rungrotmongkol T; Frecer V; De-Eknamkul W; Hannongbua S; Miertus S
Antiviral Res; 2009 Apr; 82(1):51-8. PubMed ID: 19428595
[TBL] [Abstract][Full Text] [Related]
12. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
Park JW; Jo WH
J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
[TBL] [Abstract][Full Text] [Related]
13. Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
Dao TT; Nguyen PH; Lee HS; Kim E; Park J; Lim SI; Oh WK
Bioorg Med Chem Lett; 2011 Jan; 21(1):294-8. PubMed ID: 21123068
[TBL] [Abstract][Full Text] [Related]
14. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Mitrasinovic PM
Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
[TBL] [Abstract][Full Text] [Related]
15. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
[TBL] [Abstract][Full Text] [Related]
16. Complexity in influenza virus targeted drug design: interaction with human sialidases.
Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
Albohy A; Mohan S; Zheng RB; Pinto BM; Cairo CW
Bioorg Med Chem; 2011 May; 19(9):2817-22. PubMed ID: 21489803
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of NH
Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y
Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426
[TBL] [Abstract][Full Text] [Related]
19. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Du QS; Wang SQ; Chou KC
Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Zhang H; Wang K; Zhu H; Zhao X; Zhao H; Lei Z; Chen B; Yang F; Liu K; Zhang K; Wang J; Tian Y
Eur J Med Chem; 2020 Aug; 200():112423. PubMed ID: 32512482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
